{'52WeekChange': -0.14420807,
 'SandP52WeekChange': 0.0644362,
 'address1': '805 Las Cimas Parkway',
 'address2': 'Suite 100',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 8.32,
 'askSize': 1100,
 'averageDailyVolume10Day': 166575,
 'averageVolume': 337804,
 'averageVolume10days': 166575,
 'beta': 2.073184,
 'beta3Year': None,
 'bid': 7.26,
 'bidSize': 2200,
 'bookValue': 1.469,
 'category': None,
 'circulatingSupply': None,
 'city': 'Austin',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 7.48,
 'dayLow': 6.96,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -3.435,
 'enterpriseToRevenue': None,
 'enterpriseValue': 279031840,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '512 872 5121',
 'fiftyDayAverage': 8.806714,
 'fiftyTwoWeekHigh': 11.38,
 'fiftyTwoWeekLow': 3.5,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 33010088,
 'forwardEps': -1.91,
 'forwardPE': -3.790576,
 'fromCurrency': None,
 'fullTimeEmployees': 79,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.04081,
 'heldPercentInstitutions': 0.57816005,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/aegleabio.com',
 'longBusinessSummary': 'Aeglea BioTherapeutics, Inc., a clinical-stage '
                        'biotechnology company, designs and develops human '
                        'enzyme therapeutics for the treatment of patients '
                        "with rare genetic and cancer diseases. The company's "
                        'lead product candidate includes pegzilarginase, a '
                        'recombinant human Arginase 1 enzyme which is in Phase '
                        'III PEACE trial to evaluate the safety and efficacy '
                        'for the treatment of Arginase 1 deficiency. Its '
                        'preclinical pipeline products comprise ACN00177, a '
                        'product candidate for the treatment of '
                        'homocystinuria; AEB5100, a recombinant human enzyme '
                        'that degrades plasma cystine and cysteine; AEB2109, '
                        'an engineered human enzyme that targets the '
                        'degradation of the amino acid methionine; and '
                        'AEB3103, a product candidate. The company was '
                        'formerly known as Aeglea BioTherapeutics Holdings, '
                        'LLC and changed its name to Aeglea BioTherapeutics, '
                        'Inc. in March 2015. Aeglea BioTherapeutics, Inc. was '
                        'founded in 2013 and is headquartered in Austin, '
                        'Texas.',
 'longName': 'Aeglea BioTherapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 322902528,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_253892234',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -79815000,
 'nextFiscalYearEnd': 1640908800,
 'open': 7.48,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '512 942 2935',
 'previousClose': 7.49,
 'priceHint': 2,
 'priceToBook': 4.9285226,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 7.48,
 'regularMarketDayLow': 6.96,
 'regularMarketOpen': 7.48,
 'regularMarketPreviousClose': 7.49,
 'regularMarketPrice': 7.48,
 'regularMarketVolume': 163108,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 44599800,
 'sharesPercentSharesOut': 0.0255,
 'sharesShort': 1137721,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 635333,
 'shortName': 'Aeglea BioTherapeutics, Inc.',
 'shortPercentOfFloat': 0.0274,
 'shortRatio': 2.52,
 'startDate': None,
 'state': 'TX',
 'strikePrice': None,
 'symbol': 'AGLE',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.421,
 'twoHundredDayAverage': 7.3468704,
 'volume': 163108,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.aegleabio.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '78746'}